TY - JOUR
T1 - Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer
T2 - a consensus recommendation from the EORTC Imaging and Breast Cancer Groups
AU - Pasquier, David
AU - Bidaut, Luc
AU - Oprea-Lager, Daniela Elena
AU - deSouza, Nandita M.
AU - Krug, David
AU - Collette, Laurence
AU - Kunz, Wolfgang
AU - Belkacemi, Yazid
AU - De Geus-Oei, Lioe Fee
AU - More Authors, null
N1 - Green Open Access added to TU Delft Institutional Repository ‘You share, we take care!’ – Taverne project https://www.openaccess.nl/en/you-share-we-take-care Otherwise as indicated in the copyright section: the publisher is the copyright holder of this work and the author uses the Dutch legislation to make this work public.
PY - 2023
Y1 - 2023
N2 - Breast cancer remains the most common cause of cancer death among women. Despite its considerable histological and molecular heterogeneity, those characteristics are not distinguished in most definitions of oligometastatic disease and clinical trials of oligometastatic breast cancer. After an exhaustive review of the literature covering all aspects of oligometastatic breast cancer, 35 experts from the European Organisation for Research and Treatment of Cancer Imaging and Breast Cancer Groups elaborated a Delphi questionnaire aimed at offering consensus recommendations, including oligometastatic breast cancer definition, optimal diagnostic pathways, and clinical trials required to evaluate the effect of diagnostic imaging strategies and metastasis-directed therapies. The main recommendations are the introduction of modern imaging methods in metastatic screening for an earlier diagnosis of oligometastatic breast cancer and the development of prospective trials also considering the histological and molecular complexity of breast cancer. Strategies for the randomisation of imaging methods and therapeutic approaches in different subsets of patients are also addressed.
AB - Breast cancer remains the most common cause of cancer death among women. Despite its considerable histological and molecular heterogeneity, those characteristics are not distinguished in most definitions of oligometastatic disease and clinical trials of oligometastatic breast cancer. After an exhaustive review of the literature covering all aspects of oligometastatic breast cancer, 35 experts from the European Organisation for Research and Treatment of Cancer Imaging and Breast Cancer Groups elaborated a Delphi questionnaire aimed at offering consensus recommendations, including oligometastatic breast cancer definition, optimal diagnostic pathways, and clinical trials required to evaluate the effect of diagnostic imaging strategies and metastasis-directed therapies. The main recommendations are the introduction of modern imaging methods in metastatic screening for an earlier diagnosis of oligometastatic breast cancer and the development of prospective trials also considering the histological and molecular complexity of breast cancer. Strategies for the randomisation of imaging methods and therapeutic approaches in different subsets of patients are also addressed.
UR - http://www.scopus.com/inward/record.url?scp=85166598121&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(23)00286-3
DO - 10.1016/S1470-2045(23)00286-3
M3 - Review article
C2 - 37541279
AN - SCOPUS:85166598121
SN - 1470-2045
VL - 24
SP - e331-e343
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 8
ER -
